Cabaletta Bio closes $50M Series B round for cellbased autoimmune disease therapies

Cabaletta Bio closes $50M Series B round for cell-based autoimmune disease therapies

The latest fund raise brings the total funding the company has received since May to $88 million, which it will use to develop CAAR-T therapies, similar to CAR-Ts used in cancers.

More From BioPortfolio on "Cabaletta Bio closes $50M Series B round for cell-based autoimmune disease therapies"